Thermo Fisher Scientific (TMO) Stock Price, Fundamentals & Analysis

What TMO does

Thermo Fisher Scientific (TMO) is a US stock in the Healthcare sector, specifically the Diagnostics & Research industry, headquartered in Waltham, United States. It provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. It is part of the S&P 500 and competes with peers such as Danaher Corporation (DHR), Waters Corporation (WAT), and Idexx Laboratories (IDXX).

Key numbers explained

• 665.3 USD is the current share price, representing the cost to buy one share on the market.
• The trailing P/E ratio of 35.8 shows how much investors pay per dollar of the company's last 12 months of earnings; a higher number often reflects growth expectations.
• The forward P/E ratio of 24.2 uses expected future earnings, which can make the stock look less expensive if analysts anticipate growth.
• Earnings per share, trailing 12 months of 18.58 USD indicates the portion of profit allocated to each outstanding share.
• The dividend yield of 0.29% reflects the annual dividend payment as a percentage of the share price; TMO pays a small yield, with 10% of earnings distributed as dividends.
• Beta of 0.85 suggests the stock tends to be less volatile than the overall market.
• Market cap of 245.99B USD classifies TMO as a mega-cap company by total equity value.
• Revenue, trailing 12 months of 46.34B USD with 10.5% year-over-year growth shows the scale and recent top-line expansion.

Recent news

Recent headlines highlight new product launches and market analyses. One report covers the launch of Gibco™ CHO-K1 Catalog Panel Media and Feed to accelerate biologics development. Other articles examine how Thermo Fisher is reshaping the global pharmaceutical filtration and bioreactors markets alongside competitors such as Danaher and Sartorius. Additional reports benchmark the company in gene transfer technologies and therapeutic drug monitoring against firms like Roche, Abbott, and Bio-Rad.

What to watch

Investors typically monitor TMO in the context of its exposure to life sciences R&D spending, regulatory changes affecting diagnostics, and competitive dynamics with peers like Danaher Corporation (DHR) and Waters Corporation (WAT). The company's debt-to-equity ratio of 80.6% is a factor in its financial leverage. Upcoming catalysts include the nextEarningsDate of 21 oct. 2026 and the exDividendDate of 15 sept. 2026. Broader trends in healthcare innovation and government funding for scientific research can also influence the stock.